The outcome of 67 patients operated on between 1963 and 1971 for pure mitral regurgitation due to dilatation of the mitral ring (group I: 25 cases), papillary muscle dysfunction (group II: 11 cases) and valvular and/or subvalvular lesions (group III: 31 cases) was analysed with an average follow up of 9.1 years (range 4 to 12 years). Eleven patients (16 p. 100) died in the late post-operative period (average 4 years). The main cause of death was cardiac failure related to the valvulopathy (8 cases). 11 patients were reoperated (16 p. 100) (on average 5 years after operation). The opeartive findings, besides early technical errors (2 cases), showed deterioration to be less often related to secondary dilatation of the mitral ring (1 case) than to progression of the valvular and subvalvular disease (7 cases). The patients followed up at present have shown symptomatic improvement (39 out of 40 cases) although the cardiothoracic ratio has generally remained unchanged. Average pulmonary capillary and arterial pressures were lower than the preoperative findings in 9 control cardiac catheterisations. Thromboembolism (2.6 p. 100), infection (2.6 p. 100) and haemolysis (0 p. 100) were less frequent than in patients with prosthetic valves. The survival curve is also better in patients having undergone reconstructive surgery. This study showed the best results in the group with pure mitral regurgitation secondary to mitral ring dilatation. The results were less favourable in groups II and III. This surgical technique would seem best reserved for young people, when anticoagulant therapy carries unacceptable risks, and when the following anatomical conditions are respected: pure mitral regurgitation with a normal valvular and subvalvular apparatus.

Download full-text PDF

Source

Publication Analysis

Top Keywords

pure mitral
12
mitral regurgitation
12
mitral ring
12
dilatation mitral
8
group cases
8
average years
8
cases patients
8
valvular subvalvular
8
cases
7
patients
6

Similar Publications

[Cluster analysis and analysis of risk factors for hereditary transthyretin amyloidosis cardiomyopathy].

Zhonghua Xin Xue Guan Bing Za Zhi

December 2024

Department of Cardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100730, China.

To explore the clinical characteristics and prognostic value in hereditary transthyretin amyloidosis cardiomyopathy (hATTR-CM) patients based on cluster analysis, and to explore the risk factors for cardiovascular composite events. This retrospective cohort study included hATTR-CM patients who were admitted to Peking Union Medical College Hospital from January 2000 to January 2024. These patients were divided into two clusters using cluster analysis, based on genetic information, demographic information and clinical information.

View Article and Find Full Text PDF

The novel balloon-expandable Myval transcatheter heart valve: systematic review of aortic, mitral, tricuspid and pulmonary indications.

Rev Esp Cardiol (Engl Ed)

October 2024

Servicio de Cardiología, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario, Valladolid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. Electronic address:

Article Synopsis
  • Myval technology is a new balloon-expandable option for treating heart valve issues, emerging after the established Edwards system, and its usage is increasing despite some debated points.
  • A thorough literature review covering studies from December 2016 to May 2024 showed Myval to be effective for native aortic stenosis with low mortality and complication rates, and its performance compares favorably to other devices.
  • The findings also indicate that Myval is safe for various off-label uses, achieving high success rates across different heart valve procedures, although more extensive studies are needed to confirm these results.
View Article and Find Full Text PDF

First-in-Man Experience of Telerobotic Transcatheter Edge-to-Edge Repair With Pure Echo Guidance.

JACC Cardiovasc Interv

November 2024

Department of Structure Heart Center, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China; Department of Structure Heart Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:

View Article and Find Full Text PDF

Background: In recent years, transcatheter aortic valve replacement (TAVR) has emerged as a pivotal treatment for pure native aortic regurgitation (PNAR). Given patients with severe aortic regurgitation (AR) are prone to suffer from pulmonary hypertension (PH), understanding TAVR's efficacy in this context is crucial. This study aims to explore the short-term prognosis of TAVR in PNAR patients with concurrent PH.

View Article and Find Full Text PDF
Article Synopsis
  • Transmitral myectomy for hypertrophic obstructive cardiomyopathy can be performed through minimally invasive approaches, providing an alternative to traditional surgery methods.
  • A new technique involves a longitudinal incision in the midline of the anterior mitral leaflet, allowing for septal myectomy while maintaining easier surgical access.
  • This method simplifies the procedure by avoiding the need for detaching the anterior leaflet and eliminates the use of patch materials, which can compromise the durability of the leaflets.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!